Research Paper Volume 13, Issue 2 pp 2264—2278

Silencing LINC00482 inhibits tumor-associated inflammation and angiogenesis through down-regulation of MMP-15 via FOXA1 in bladder cancer

Silencing LINC00482 suppresses progression of bladder cancer in vivo. (A) Tumor volume in each group after injection of sh-MMP15, sh-LINC00482 and oe-MMP15; (B) immunohistochemistry of COX-2; (C) immunohistochemistry of MVD; (D) the expression of MMP15, VEGF, and NF-κB detected by Western blot analysis. The measurement data were presented as mean ± standard deviations, n = 8. Differences between two groups were compared by unpaired t test. Repeated measurement analysis of variance was used to compare the proliferation ability at different time points, and Tukey’s was used for post-hoc tests. * p vs. the sh-NC + oe-NC group; # p vs. the sh-LINC00482 + oe-NC group.

Figure 6. Silencing LINC00482 suppresses progression of bladder cancer in vivo. (A) Tumor volume in each group after injection of sh-MMP15, sh-LINC00482 and oe-MMP15; (B) immunohistochemistry of COX-2; (C) immunohistochemistry of MVD; (D) the expression of MMP15, VEGF, and NF-κB detected by Western blot analysis. The measurement data were presented as mean ± standard deviations, n = 8. Differences between two groups were compared by unpaired t test. Repeated measurement analysis of variance was used to compare the proliferation ability at different time points, and Tukey’s was used for post-hoc tests. * p < 0.05 vs. the sh-NC + oe-NC group; # p < 0.05 vs. the sh-LINC00482 + oe-NC group.